Show Summary Details
Page of

Drug Dosing in Continuous Renal Replacement Therapy 

Drug Dosing in Continuous Renal Replacement Therapy
Chapter:
Drug Dosing in Continuous Renal Replacement Therapy
Author(s):

Adrian Wong

, Sandra L. Kane-Gill

, and John A. Kellum

DOI:
10.1093/med/9780190225537.003.0020
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 01 June 2020

Acute kidney injury (AKI) in the intensive care unit (ICU) occurs in 5 to 25% of patients. Of this population, approximately 6% require renal replacement therapy (RRT). Mortality in patients requiring RRT is estimated to be even higher than in patients with AKI not requiring RRT (60%), approaching up to 80%. Modes of RRT include intermittent hemodialysis (IHD) or continuous renal replacement therapy (CRRT). CRRT offers the potential advantage of continuous removal of fluid and solutes, reducing potential fluctuations in electrolytes, fluid balance, and hemodynamic stability, compared to IHD. Although there is ongoing debate regarding the optimal use and application of RRT in the ICU, its frequent use necessitates drug dosing considerations. Along with the numerous comorbidities and physiologic factors that may affect drug dosing in critically ill patients, RRT only adds to the complicated nature of these patients.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.